Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Vitality Biopharma, Inc. (OTC: VBIO).

Full DD Report for VBIO

You must become a subscriber to view this report.


Recent News from (OTC: VBIO)

Vitality Biopharma Discovers and Patents Use of Cannabinoids for C.diff-Associated Diarrhea and Colitis
- Vitality’s GI-targeted VBX-100 THC compound to be investigated as treatment of recurrent C. difficile infections LOS ANGELES, May 10, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedica...
Source: GlobeNewswire
Date: May, 10 2018 08:30
Vitality Biopharma Sparks Canadian Cannabinoid Genetics R
Canada’s role in the emerging cannabinoid revolution just took another step forward this week—further highlighting that the country will be at the forefront of development for the foreseeable future. The makers of a new form of cannabinoid prodrugs called “cannabosides,...
Source: Livemoney
Date: April, 16 2018 08:30
Vitality Biopharma Launches Canadian Subsidiary Focused on Cannabinoid Genetics R&D
-Wholly-owned subsidiary to enable access to best available cannabinoid compounds in a federally-compliant manner and facilitate key collaborative research programs LOS ANGELES, April 05, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the &#x...
Source: GlobeNewswire
Date: April, 05 2018 09:00
Revolutionary Cannabinoid Prodrug Goes Global with International Patent Prosecution
A new form of cannabinoid prodrugs called “cannabosides”, which were discovered using innovative biosynthesis methods originally developed for improving the taste of stevia, are now set to be recognized around the world, and could revolutionize treatment for serious conditions s...
Source: Livemoney
Date: March, 28 2018 09:22
Vitality Biopharma Files Intellectual Property in All Major Pharmaceutical Markets Worldwide
THC prodrugs including VBX-100 designed to deliver cannabinoids for targeted therapeutic effects without psychoactivity LOS ANGELES, March 28, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedica...
Source: GlobeNewswire
Date: March, 28 2018 08:30
Vitality Biopharma CEO Robert Brooke Provides Shareholder Letter
LOS ANGELES, March 19, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment o...
Source: GlobeNewswire
Date: March, 19 2018 08:00
The Story Behind Growth: New Report Discusses Vitality Biopharma and Growlife - Emerging Trends Within New Industry
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Vitality Biopharma, Inc. ( OTCQB: VBIO ) and Growlife, Inc. ( OTC PINK: PHOT ), including recent technical analysis and consolidated fundamental informa...
Source: ACCESSWIRE IA
Date: February, 28 2018 08:30
SeeThruEquity Issues Update on Vitality Biopharma, Inc. (VBIO)
NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Vitality Biopharma, Inc. and updated its target price to $3.00. The re...
Source: ACCESSWIRE IA
Date: January, 30 2018 09:00
A New, Non-Corrosive, Non-Irritating Treatment for Pediatric Ulcerative Colitis Has Been Submitted for FDA's Orphan Drug Classification
The US Federal Drug Administration (FDA) has received an orphan drug designation request from Vitality Biopharma Inc. (OTCQB: VBIO)—a cannabinoid prodrug pharma corporation in the process of developing its flagship asset VITA-100, targeting the treatment of pediatric ulcerative colitis...
Source: Livemoney
Date: January, 29 2018 09:01
Vitality Biopharma Applies for Orphan Drug Status
Vitality Biopharma, Inc. (OTCQB: VBIO) announced it submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration (FDA). Vitality hopes to gain VITA-100’s approval as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form ...
Source: Pot News
Date: January, 23 2018 00:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-171.461.4081.491.32435,406
2018-08-161.431.4951.501.4369,139
2018-08-151.511.501.541.45113,206
2018-08-141.551.531.551.42104,441
2018-08-131.491.541.591.4980,636

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17204,224442,45646.1569Short
2018-08-1619,61469,14928.3648Cover
2018-08-1554,111113,49047.6791Short
2018-08-1444,026104,43742.1556Short
2018-08-1319,27580,53623.9334Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VBIO.


About Vitality Biopharma, Inc. (OTC: VBIO)

Logo for Vitality Biopharma, Inc. (OTC: VBIO)

Vitality Biopharma is developing proprietary cannabinoid pharmaceuticals for treatment of serious neurological and inflammatory disorders. Vitality s targeted prodrug technology enables delivery of cannabinoids to the site of disease while reducing or eliminating psychoactivity.

 

 

 

Current Management

  • Robert Brooke / CEO
    • Robert Brooke has served as a director and our Chief Executive Officer since January , . Mr. Brooke was a founder of Genesis Biopharma now known as Iovance Biotherapeutics NASDAQ: IOVA , a cancer immunotherapy company, where he served as Director, President and Chief Executive Officer from March until February . Mr. Brooke is a cofounder of Intervene Immune, Inc., a privately held biotechnology company focused on immune regeneration, and since March has served on a limited parttime basis as Chief Executive Officer. From to , he was an analyst with Bristol Capital Advisors, LLC, investment manager to Bristol Investment Fund, Ltd. Bristol . During this period, Bristol financed over public healthcare and life science companies and was listed by The PIPEs Report in as being the most active investor in private placements by public biotechnology companies. Mr. Brooke earned a B.S. in Electrical Engineering from Georgia Tech in and a M.S. in Biomedical Engineering from UCLA in .
  • Richard McKilligan / Counsel, Controller, Corporate Secretary
  • Avtar Dhillon / Chairman
    • As former president and CEO of Inovio Pharmaceuticals, Inc. formerly Inovio Biomedical Corporation , Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over million and secured more than million in licensing deals from global companies including Merck and Wyeth now Pfizer . Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.
  • Robert Brooke /
    • Robert Brooke has served as a director and our Chief Executive Officer since January , . Mr. Brooke was a founder of Genesis Biopharma now known as Iovance Biotherapeutics NASDAQ: IOVA , a cancer immunotherapy company, where he served as Director, President and Chief Executive Officer from March until February . Mr. Brooke is a cofounder of Intervene Immune, Inc., a privately held biotechnology company focused on immune regeneration, and since March has served on a limited parttime basis as Chief Executive Officer. From to , he was an analyst with Bristol Capital Advisors, LLC, investment manager to Bristol Investment Fund, Ltd. Bristol . During this period, Bristol financed over public healthcare and life science companies and was listed by The PIPEs Report in as being the most active investor in private placements by public biotechnology companies. Mr. Brooke earned a B.S. in Electrical Engineering from Georgia Tech in and a M.S. in Biomedical Engineering from UCLA in .
  • Anthony E. Maida /

Current Share Structure

  • Market Cap: $45,735,858 - 03/09/2018
  • Authorized: 1,000,000,000 - 02/08/2018
  • Issue and Outstanding: 24,200,147 - 02/14/2018
  • Float: 18,466,590 - 05/31/2017

 


Recent Filings from (OTC: VBIO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: March, 02 2018
Amendment to general form for registration of securities under the Securities Act of 1933
Filing Type: S-1/AFiling Source: edgar
Filing Date: February, 28 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 14 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: January, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 19 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 13 2017
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: December, 07 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: VBIO)

Daily Technical Chart for (OTC: VBIO)


Stay tuned for daily updates and more on (OTC: VBIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: VBIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VBIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of VBIO and does not buy, sell, or trade any shares of VBIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/